



The Microbiota Gut axis and Their Role in Inflammation, Autoimmunity and Multi Organ Diseases as a Therapeutic Target

Sanaz Momen¹, Neda Soleimani ^{1,*}

¹ Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran

*Corresponding Author: Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran. Email: n_soleimani@sbu.ac.ir

Received: 26 April, 2025; Revised: 13 August, 2025; Accepted: 17 August, 2025

Abstract

Context: The gut microbiome, composed of microorganisms within our digestive system, is essential for gut health and is associated with various diseases.

Methods: Research conducted from 2010 to 2025 indicates that dysbiosis, an imbalance in gut bacteria, is linked to conditions such as inflammatory bowel disease (IBD), cancer, brain disorders, autoimmune diseases, and heart issues.

Results: Dysbiosis, characterized by reduced microbial diversity and an increase in harmful bacteria, significantly contributes to IBD, irritable bowel syndrome (IBS), chronic inflammation in cancer, and autoimmune diseases.

Conclusions: Maintaining a balanced gut microbiome is crucial for overall health, and interventions such as fecal microbiota transplantation (FMT), probiotics, and high-fiber diets can restore balance and alleviate symptoms.

Keywords: Gut Microbiome, IBD, IBS, Dysbiosis, GERD, Colorectal Cancer, MS, Neurological

1. Context

The gut microbiome, composed of trillions of microorganisms, is crucial for health, aiding in digestion, immune function, and metabolism. However, imbalances can lead to inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and metabolic disorders. Gut bacteria are also associated with diseases such as colorectal cancer (CRC), cardiovascular issues, and neurological disorders. Treatments such as fecal microbiota transplantation (FMT) and probiotics are being studied, highlighting the vital role of the microbiome in health and its ability to restore balance (1). This review synthesizes current evidence on the role of gut microbiota in inflammation, focusing on mechanistic insights and therapeutic potential, and addressing specific questions:

1. How does gut dysbiosis contribute to the pathogenesis of inflammatory (e.g., IBD), autoimmune (e.g., MS, T1D), and metabolic diseases (e.g., obesity, CVD)?

2. What are the key microbial metabolites (e.g., SCFAs, TMAO) and pathways linking gut microbiota to extra-intestinal diseases (e.g., neurodegenerative disorders)?

3. How can microbiome-targeted therapies (e.g., FMT, probiotics, dietary interventions) modulate disease outcomes?

Recent studies reveal gaps in causality evidence, and we suggest future research directions for clinical translation.

2. Methods

2.1. Search Strategy and Selection Criteria

The systematic literature search was conducted to identify studies on the gut microbiota's role in inflammation, autoimmunity, and multi-organ diseases. Our systematic approach included:

1. Engines & databases: PubMed/MEDLINE, Google Scholar, Web of Science with Keywords like Gut Microbiome, IBD, IBS, Dysbiosis, GERD, CRC.

2. Search strategy: Searches review articles from 2010 to 2025.

3. Screening process: Initially, about 90 articles were reviewed. The information from 54 articles was utilized.

4. Selection criteria:

- Inclusion: Original research articles, Systematic reviews and meta-analyses, Clinical trials, Studies with clear methodology and outcomes, Publications in peer-reviewed journals.

- Exclusion: Review articles with <10 subjects

The search strategy was designed to be comprehensive yet focused on our research questions about microbiota-disease interactions and therapeutic potential.

2.2. Gut Microbiota and Dysbiosis

The gut microbiome, a community of microorganisms in the digestive system, is crucial for digestive health and disease progression. It evolves throughout life, with imbalances (dysbiosis) linked to disorders like IBD, IBS, and cancers, influenced by genetics and environmental factors (2).

3.3. Factors Influencing the Balance of the Normal Microbiota Populations

3.3.1. Environmental Factors

Environmental factors like lifestyle choices, living conditions, antibiotic use, and exposure to harmful substances impact health. Overuse of antibiotics harms gut bacteria, urban living decreases microbial diversity, and pollutants impact the microbiome (3).

3.3.2. Genetic Factors

Genes significantly influence gut bacteria through their effects on the immune system and gut health. Variants in genes like NOD2 and IL23R can increase the risk of Crohn's disease and IBD. MUC2 mutations raise colitis risk, while metabolism-related genes such as FTO and ABCB11 impact bacterial growth. Variations in LCT are associated with beneficial Bifidobacterium for lactose digestion. Understanding these factors is crucial for evaluating disease risk and developing targeted IBD therapies (4).

3.4. The Gut Microbiota and Its Role in Inflammation and Immune Regulation, and Surrogate Factors to Detect Theses Condition

C-reactive protein (CRP) is an inflammatory marker produced by the liver in response to cytokines like TNF- α and IL-6. Elevated CRP levels indicate inflammation associated with conditions like IBS, (IBD, and CRC. While some IBS patients may show increased CRP, it's more typically linked to IBD and chronic inflammation, which elevate cancer risk (5). The gut microbiome significantly influences CRP levels, with pathogenic bacteria increasing CRP, while beneficial metabolites, particularly short-chain fatty acids (SCFAs), may lower it. A healthy gut microbiome is vital for regulating immune responses and preventing chronic inflammation, as dysbiosis can lead to broader health issues (6).

3.5. Pathophysiology of Inflammatory and Autoimmune Diseases in Relation to Gut Dysbiosis

3.5.1. Multiple Sclerosis

Multiple Sclerosis is an autoimmune disease affecting the nervous system, resulting in brain and spinal cord inflammation. Genetic and environmental factors, along with the gut microbiome, play a role in MS. Dysbiosis in gut bacteria can hinder immune function and increase inflammation. Healthy bacteria are crucial for neurotransmitter release, while imbalances can trigger harmful immune responses. Beneficial bacteria produce SCFAs that support the blood-brain barrier and reduce swelling. Research shows that MS patients have fewer beneficial bacteria, such as Bacteroides fragilis and Faecalibacterium prausnitzii, leading to increased inflammation and higher levels of pro-inflammatory bacteria like Akkermansia muciniphila. Gut microbiome disruptions also affect tryptophan metabolism, with MS patients exhibiting lower levels of secondary bile acids, which are vital for reducing inflammation and supporting T cell function (7).

3.6. Microbiota-Gut Axis and Cardiometabolic Diseases

3.6.1. Type 1 Diabetes and Type 2 Diabetes

Research shows significant differences in gut microbiomes between Type 1 diabetes (T1D) and Type 2 diabetes (T2D).

T1D features dysbiosis, with increased harmful bacteria like Bacteroides and Clostridium and decreased beneficial ones such as Lactobacillus and

Bifidobacterium. This imbalance can impair immune function, insulin production, gut permeability, and inflammation. In contrast, T2D involves insulin resistance, where the gut microbiome contributes through beneficial metabolites like SCFAs. Butyrate from Firmicutes, like *Faecalibacterium prausnitzii*, improves insulin response and reduces inflammation. A diverse microbiota, particularly with more Bacteroidetes, is associated with better glucose regulation and lower diabetes risk (8).

3.6.2. Cardiovascular Diseases

Alterations in the gut microbiome are linked to cardiovascular diseases (CVD) such as atherosclerosis and hypertension; gut bacteria affect lipid metabolism, blood pressure, and systemic inflammation. Choline metabolism by gut microbes produces TMAO, a compound that raises cardiovascular risk when levels are high. Dysbiosis can lead to increased TMAO and inflammation, worsening heart health. People with heart disease often have reduced SCFA-producing bacteria, which play a protective role. Polycystic ovary syndrome (PCOS) raises cardiovascular risk with changes in the gut microbiome, inflammation, and hormonal imbalance contributing to increased arterial wall thickness and early signs of atherosclerosis (9).

3.6.3. Obesity and Cardio-Metabolic Health

Obesity is a significant risk factor for cardiometabolic disorders, including cardiovascular disease, type 2 diabetes, hypertension, and chronic kidney disease. Its prevalence has reached pandemic levels, particularly in Western countries, increasing morbidity and mortality (10).

3.6.4. How Gut Microbiota Influence Obesity and Cardiometabolic Risk

The gut microbiome is vital for energy extraction, nutrient uptake, and regulating hormones such as GLP-1, which impacts feelings of fullness and glucose processing. An imbalance in gut bacteria can increase gut permeability, leading to chronic inflammation and metabolic disorders. Changes in gut composition are linked to insulin resistance and metabolic syndrome, with obesity often characterized by reduced microbial diversity and an increase in pro-inflammatory bacteria, which worsens metabolic dysfunction (11, 12).

3.7. Microbiota-Gut Axis and Gastrointestinal Diseases and Cancers

Research indicates that individuals with IBD and IBS have lower gut bacterial diversity compared to healthy individuals, with a decrease in beneficial bacteria from the Firmicutes and Bacteroidetes phyla, such as *Lactobacillus* and *Bifidobacterium*. This reduction affects fiber digestion and short-chain fatty acid production, which is crucial for gut health, while harmful bacteria like Proteobacteria may increase, leading to issues like leaky gut and inflammation. In IBD, the loss of Firmicutes disrupts the microbial balance and reduces beneficial species like *Faecalibacterium prausnitzii*. In IBS-C, characterized by constipation, levels of *Methanobrevibacter smithii* may rise, worsening the condition (13).

3.8. Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease (GERD) is a chronic condition where stomach acid irritates the esophagus, leading to heartburn and chest pain. Recent studies suggest that the gut microbiome may influence esophageal motility and inflammation, potentially exacerbating GERD symptoms and impacting immune function (14).

3.8.1. Specific Microbial Changes in Gastroesophageal Reflux Disease

In GERD patients, the Firmicutes to Bacteroidetes ratio alters, impacting gastric acid regulation and motility. A decrease in beneficial *Lactobacillus* bacteria can lead to increased esophageal inflammation and worsen acid reflux (15).

3.8.2. Gastrointestinal Cancers and the Gut Microbiome

Gut microbiota influences early cancer development through immune responses, inflammation, and DNA repair. While some microbes produce carcinogenic metabolites, others support immune function and epithelial health. Imbalances in gut bacteria can lead to inflammatory responses that damage DNA and activate cancer-promoting pathways, such as NF- κ B (16).

3.8.3. Carcinogenic Metabolites

Colorectal cancer is linked to gut bacteria, showing lower levels of beneficial types like Bifidobacteria and Lactobacilli, while harmful bacteria such as

Fusobacterium nucleatum and *Bacteroides fragilis* are elevated. These harmful bacteria can cause inflammation and DNA damage, whereas beneficial compounds like butyrate promote colon health. Gastric cancer is associated with *Helicobacter pylori*, which contributes to chronic inflammation and gut dysbiosis. Esophageal cancer is connected to harmful bacteria as well, with GERD further disrupting the microbial balance. These findings highlight the need for more research on gut microbiota's impact on cancer for potential treatment and prevention (17).

3.8.4. Microbiota-Gut Axis and Liver Diseases and Cancers

In cirrhosis, chronic liver damage increases intestinal permeability, or "leaky gut," allowing harmful bacteria like *E. coli* into the bloodstream. This triggers inflammation and immune responses activated by lipopolysaccharides (LPS), leading to more severe liver damage and fibrosis. Cirrhosis alters the gut microbiome, reducing beneficial SCFAs and increasing harmful substances. Bacteria convert dietary components into trimethylamine (TMA), which the liver processes into trimethylamine N-oxide (TMAO), which is linked to liver and heart issues. Additionally, altered bile acids increase fat metabolism and inflammation, further harming the liver (18).

3.8.4.1. Relationship Between Non-fatty Liver Disease, Steatohepatitis, Hepatocellular Carcinoma, and the Gut Microbiota

The gut microbiota significantly influences the progression of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC) through dysbiosis. In NAFLD, dysbiosis increases intestinal permeability, allowing harmful microbial products like lipopolysaccharides (LPS) to reach the liver, leading to inflammation and lipid accumulation. In NASH, it activates inflammasome pathways and disrupts metabolism, causing liver injury and fibrosis. For HCC, chronic inflammation and dysbiosis facilitate bacterial translocation, promoting carcinogenesis through DNA damage and immune suppression. Overall, gut microbiota dysregulation connects NAFLD, NASH, and HCC, suggesting microbiome modulation as a potential therapeutic target (19).

3.9. Microbiota-Gut Axis and Neurological and Neurodegenerative Disorders

In Alzheimer's disease (AD), bacteria like *Fusobacterium nucleatum* increase gut permeability and inflammation, contributing to amyloid beta accumulation. Elevated *Bacteroides* species are also linked to gut inflammation that negatively impacts brain health and promotes amyloid plaques (20). Parkinson's disease (PD) is a fast-progressing neurodegenerative disorder marked by the gradual loss of dopamine-producing neurons in the substantia nigra and reduced dopamine activity in the striatum (21). The gut microbiome affects disease progression, as gut inflammation disrupts bacterial balance and causes leaky gut syndrome. This permits harmful substances to enter the bloodstream, leading to brain inflammation and nerve damage. Misfolded alpha-synuclein can reach the brain via the vagus nerve, with *Enterococcus faecalis* involved. Beneficial bacteria like *Prevotella*, *Lactobacillus*, and *Bifidobacterium* are diminished in PD, reducing protective SCFAs and worsening gut inflammation. Understanding these bacteria is crucial for revealing the mechanisms behind these neurodegenerative diseases (22).

3.10. Techniques and Markers for Assessing the Gut Microbiota

Imbalances in gut microbiota can result in gastrointestinal issues, obesity, insulin resistance, and inflammation. Researchers use methods like 16S rRNA sequencing and metagenomic sequencing to associate specific bacteria with diseases and investigate microbial metabolism. Metabolomics helps identify imbalances, such as elevated lipopolysaccharides in cirrhosis, while FMT shows promise for restoring gut health, especially in *Clostridium difficile* infections. Inflammatory markers like TNF- α and CRP are significant in conditions like IBD and type 2 diabetes. Flow cytometry tests analyze these markers, and host genetics play a role in microbiome functionality, paving the way for personalized gut health strategies (23).

3.11. Microbiota-Gut Axis and Therapeutic Potential of These

Microbiome-based therapy restores gut bacteria balance to address gastrointestinal issues, mainly through FMT. This method effectively treats recurrent *Clostridium difficile* infections and may benefit conditions like IBD and IBS (23).

But how FMT Works (24)? Fecal microbiota transplantation is a treatment that helps bring back a healthy balance of gut bacteria, mainly for people with

repeated *Clostridium difficile* infections. It starts with choosing a healthy donor who is tested to make sure they do not have infections, chronic illnesses, or gut problems. Their stool, fresh or frozen, is mixed with saline, filtered, and prepared for use. Fecal microbiota transplantation can be given in several ways: By colonoscopy straight into the colon, by enema, in capsules containing freeze dried bacteria, or through a tube reaching the upper digestive tract. Colonoscopy works best for recurrent *Clostridium difficile*, while capsules are an easier, non-invasive option. It works by adding beneficial bacteria that displace harmful ones, restoring essential compounds such as SCFAs and antimicrobial peptides, and supporting the immune system to function more normally in non-C conditions. Under different conditions, results may be temporary. The FDA currently approves FMT only for recurrent *Clostridium difficile*, with 80 - 90% success. Some of these uses are listed in [Table 1](#).

Microbiome therapies, including probiotics, prebiotics, and synbiotics, are gaining attention for treating digestive conditions. Probiotics such as *Lactobacillus rhamnosus* and *Bifidobacterium longum* may reduce inflammation in IBD and IBS, while prebiotics like inulin supports the growth of beneficial bacteria. Synbiotics enhance gut microbiome diversity. Additionally, biological drugs like infliximab and adalimumab target the immune system to reduce IBD inflammation. Alternatives such as ustekinumab and vedolizumab are available for those unresponsive to anti-TNF therapies, and small molecule inhibitors like tofacitinib and ozanimod help control immune responses. Advancements in multi-omics technologies are improving biomarker identification for targeted treatments. While current IBS and IBD therapies are effective, side effects remain a concern, highlighting the need for new strategies such as probiotics, FMT, and phage therapy for better management ([Table 2](#)) (33).

3.12. Diet Influences the Gut Microbiome

Dietary factors significantly impact the gut microbiome, which is essential for immune function and metabolism ([Table 3](#)). Fiber, particularly indigestible carbohydrates, promotes the production of beneficial SCFAs, while high-fat and high-sugar diets harm beneficial bacteria. Proteins, including both plant and

animal sources, also affect gut health. Polyphenols from fruits, vegetables, and teas support beneficial bacteria and inhibit pathogens. Mediterranean diets, low-FODMAP diets, and probiotics improve gut health, although individual responses vary based on gut bacteria and genetics (41).

4. Discussion

This review highlights the pivotal role of the gut microbiome in modulating inflammation, immunity, and multi-organ diseases. Key findings demonstrate that dysbiosis contributes to conditions ranging from IBD and IBS to cardiovascular and neurodegenerative disorders, primarily through:

1. Microbial metabolites: The balance between protective SCFAs and harmful TMAO/LPS dictates disease progression.
2. Barrier disruption: Increased intestinal permeability ("leaky gut") drives systemic inflammation.
3. Therapeutic potential: FMT and probiotics show promise, but efficacy varies by disease (e.g., > 80% success in *C. difficile* vs. 50 - 70% in IBD).

Causality remains unclear in human studies, and microbiome heterogeneity complicates universal treatments. Personalized approaches (e.g., microbiome profiling) and advanced therapies (e.g., phage-CRISPR) may bridge the gap between research and clinical application.

3.1. Conclusions

The gut microbiome is crucial for digestive health and can influence diseases such as IBD, IBS, GERD, and liver cirrhosis. Dysbiosis can cause inflammation and impact immunity, metabolism, and cardiovascular health. Treatments like FMT and probiotics, along with 16S rRNA sequencing, offer potential solutions, with future research needed on causal mechanisms and dietary interventions.

Acknowledgements

I would like to acknowledge Dr. Neda Soleimani for her support in the preparation of this manuscript.

Table 1. Clinical Outcomes of Fecal Microbiota Transplantation in Disease Treatment

Disease	Clinical Outcomes	Safety Profile	Key Supporting Studies	FMT Administration Method	Ref.
Clostridioides difficile Infection	Resolution of diarrhea; prevention of recurrence	Minor adverse events: Diarrhea, abdominal pain; Hospitalizations possibly related to FMT	Tariq et al. USA, systematic review and meta-analysis, 2019; 13 trials (610 patients); overall FMT cure rate 76.3%, lower rates in RCTs (67.7%) vs. open-label studies (82.7%).	Colonoscopy (superior to enema)	(25, 26)
Crohn's Disease	Induction of clinical remission- Steroid-free remission	No serious adverse events reported- Upper GI route showed higher early efficacy than lower delivery route	Cui, Zhou, Zhang, Zhao, Cong, China, prospective, Cohort, 2021; 174 patients; 72.7% improvement in abdominal pain; 61.6% in diarrhea; 50% steroid-free remission	Upper gastrointestinal route	(27, 28)
Metabolic Syndrome	Improved glycemic parameters; improved lipid profile	Only minor adverse events reported (fever, headache, nausea/vomiting); no serious adverse effects	Kootte et al. Netherlands; randomized controlled trial, 2017; 38 male patients with metabolic syndrome; significant improvement in insulin sensitivity at 6 weeks (12% increase); small but significant decrease in HbA1c at 6 weeks. Effects disappeared by 18 weeks; modest improvements in lipid parameters	Oral capsules (freeze-dried microbiota)	(29, 30)
Ulcerative Colitis	Evolving therapeutic application; initially approved for <i>C. difficile</i> infection	Safety profile under investigation for this indication	Paramsothy et al. Australia; multicentre randomized controlled trial, 2017; Sample Size 81; intensive multidonor FMT improved steroid-free remission in UC vs. placebo (27% vs 8%, P = 0.02).	Colonoscopy with repeated enemas	(31, 32)

Abbreviations: FMT, fecal microbiota transplantation.

Table 2. Novel Methods for Targeted Gut Microbiota Modification

Technology	Mechanism	Potential Applications	Advantages	Key Supporting Studies	Ref.
CRISPR-loaded virus	Gene editing of bacterial genomes within the gut	Precise modification of specific bacterial populations; potential treatment for microbiome-related diseases	High precision; can target bacteria already established in gut; potential for long-term effects	Lam et al. (2021, 2025), USA; animal study (mouse proof-of-concept); M13 phage delivering CRISPR-Cas9 to <i>E. coli</i> ; Stable gene editing of gut bacteria via phage CRISPR in mice, altering <i>E. coli</i> and microbiome composition.	(34)
Phage therapy	Bacteriophages target and kill specific bacteria	Alternative to antibiotics for bacterial infections; treatment of antibiotic-resistant infections	High host specificity; Bactericidal effect; self-propagating at infection site; Low toxicity	Wortelboer et al. (2023), Netherlands; double-blind randomized controlled trial (FFT-phage-rich); 24 healthy adults; gut phage administration; administered gut phages; transient alteration of recipient phageome and gut microbiota. Well-tolerated, safe.	(35, 36)
Nano synergistic therapy	Synergy between gut microbiota and nanotechnology	Colorectal cancer CRC treatment; enhanced delivery of therapeutic agents	Targeted delivery to specific gut regions; improved bioavailability of therapeutics	Han et al. South Korea, China; Animal interventional study, Mouse (<i>E. coli</i> -induced dysbiosis); Synbiotics with nanoprebiotics (phthalyl pullulan nanoparticles); Synbiotics using nanoprebiotics (phthalyl pullulan nanoparticles) significantly suppressed <i>E. coli</i> , restored gut barrier, increased microbial diversity and beneficial taxa.	(37, 38)
Engineered microbiome-modulating approaches	Novel engineering strategies for gut microbiota modulation	Ameliorating side effects of cancer treatments; enhancing efficacy of immunotherapy and chemotherapy	Overcomes gastrointestinal barriers; enhances target-specific delivery; improves drug bioavailability	Arnold et al. (2023), USA; Review & Preclinical research; synthetic biology tools for native gut bacteria; developed gene circuits for <i>E. coli</i> and Bacteroides, modulating microbiome metabolites and immune response.	(39, 40)

Table 3. Effects of Lifestyle Factors and Interventions on Gut Microbiota

Intervention	Effects on Gut Microbiota	Clinical Outcomes	Key Supporting Studies	Ref.
Weight loss	Increased α -diversity; Reduced intestinal permeability; Increased abundance of Akkermansia	Each kg of weight loss associated with increase in α -diversity; reduction in intestinal permeability	Koutoukidis et al. UK, 2022; Systematic Review & Meta-Analysis; 1,916 participants (47 trials); each kg weight loss = 0.012 \uparrow α -diversity; \uparrow Akkermansia abundance	(42)
Mediterranean diet	Increased microbial diversity; higher percentage of SCFAs and fiber-degrading bacteria; increased butyrate-producing bacteria	Reduced TMAO concentration in urine; - potentially reduced incidence of CRC; Improved cardio-metabolic health	Khavandegar et al. Iran, 2024; Systematic Review; 37 studies; MD adherence linked to clinical improvements (glycemia, inflammation, reduced fat mass)	(43, 44)
Ketogenic diet	Altered proportions of Actinobacteria, Bacteroidetes, and Firmicutes; significant changes in 19 bacterial genera; decrease in Bifidobacteria	Potential anti-inflammatory effects via ketone body influence on gut microbiome; shifted microbiome correlates with ketone body production	Ang et al. Switzerland, 2025; randomized Controlled Trial; 76 overweight/obese individuals; a very low-calorie ketogenic diet improved gut microbial diversity and increased Akkermansia.	(45)
Low-carbohydrate diet	Reduced fiber-consuming bacteria; Decreased beneficial bacteria that produce SCFAs	Potential digestive discomfort (constipation, nausea); disruption in gut microbiome diversity	Li et al. China, 2024; Interventional (before-after); Sample Size 43; 79% of participants lost > 5% weight after a 4-week low-calorie diet	(46, 47)
Semaglutide	Restored beneficial flora (Akkermansia, Faecalibaculum, Allobaculum); suppressed excessive bacterial abundance; negatively correlated with obesity indicators	Increased tight junction proteins; repaired intestinal barrier function; reduced body weight gain and improved glucose metabolism	Duan et al. China, 2024; Animal study (HFD-induced obese mice); 4 experimental groups; Semaglutide reduced weight gain, improved insulin sensitivity, and increased Akkermansia, which inversely correlated with obesity.	(48)
Probiotics	Increased beneficial bacteria abundance; regulated gut microbiota composition	Boosted immune function; improved intestinal barrier integrity; ameliorated symptoms of multiple diseases	Song et al. Korea; Randomized Controlled Trial; obese adults; B. breve + <i>L. plantarum</i> (12-week administration); no significant change in alpha/beta diversity; improved metabolic markers	(49, 50)

Footnotes

Authors' Contribution: S. M.: Writing an original draft; N. S.: Writing – review and editing. All authors reviewed and agreed on the publication of the manuscript.

Conflict of Interests Statement: The authors declare that there are no competing financial interests.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication.

Funding/Support: This research did not receive any funding.

References

- Amon P, Sanderson I. What is the microbiome? *Arch Dis Child Educ Pract Ed.* 2017;**102**(5):257-60. [PubMed ID: 28246123]. <https://doi.org/10.1136/archdischild-2016-311643>.

2. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. *Therap Adv Gastroenterol*. 2013;**6**(4):295-308. [PubMed ID: 23814609]. [PubMed Central ID: PMC3667473]. <https://doi.org/10.1177/1756283X13482996>.
3. Tetel MJ, de Vries GJ, Melcangi RC, Panzica G, O'Mahony SM. Steroids, stress and the gut microbiome-brain axis. *J Neuroendocrinol*. 2018;**30**(2). [PubMed ID: 29024170]. [PubMed Central ID: PMC6314837]. <https://doi.org/10.1111/jne.12548>.
4. Caitriona MG, Paul DC. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. *Therap Adv Gastroenterol*. 2013;**6**(4):295-308. [PubMed ID: 23814609]. [PubMed Central ID: PMC3667473]. <https://doi.org/10.1177/1756283X13482996>.
5. Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. *Life (Basel)*. 2021;**11**(12). [PubMed ID: 34947906]. [PubMed Central ID: PMC8707558]. <https://doi.org/10.3390/life11121375>.
6. Estrada JA, Contreras I. Nutritional Modulation of Immune and Central Nervous System Homeostasis: The Role of Diet in Development of Neuroinflammation and Neurological Disease. *Nutrients*. 2019;**11**(5). [PubMed ID: 31096592]. [PubMed Central ID: PMC6566411]. <https://doi.org/10.3390/nu11051076>.
7. Probstel AK, Baranzini SE. The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the "MS Microbiome". *Neurotherapeutics*. 2018;**15**(1):126-34. [PubMed ID: 29147991]. [PubMed Central ID: PMC5794700]. <https://doi.org/10.1007/s13311-017-0587-y>.
8. Zhang YJ, Li S, Gan RY, Zhou T, Xu DP, Li HB. Impacts of gut bacteria on human health and diseases. *Int J Mol Sci*. 2015;**16**(4):7493-519. [PubMed ID: 25849657]. [PubMed Central ID: PMC4425030]. <https://doi.org/10.3390/ijms16047493>.
9. Hosseini A, Pakniat H, Zafari F, Rahimian MA, Najafzade V. Poly Cystic Ovary Syndrome (PCOS): Inflammation, Hormonal Imbalance, Cardiovascular Risks, and Metabolic Factors. *Journal of Inflammatory Diseases*. 2023;**27**(2).
10. Yahiro AM, Wingo BC, Kunwor S, Parton J, Ellis AC. Classification of obesity, cardiometabolic risk, and metabolic syndrome in adults with spinal cord injury. *J Spinal Cord Med*. 2020;**43**(4):485-96. [PubMed ID: 30620685]. [PubMed Central ID: PMC7480648]. <https://doi.org/10.1080/10790268.2018.1557864>.
11. Sasidharan Pillai S, Gagnon CA, Foster C, Ashraf AP. Exploring the Gut Microbiota: Key Insights Into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes. *J Clin Endocrinol Metab*. 2024;**109**(11):2709-19. [PubMed ID: 39040013]. [PubMed Central ID: PMC11479700]. <https://doi.org/10.1210/clinem/dgae499>.
12. Gabriel CL, Ferguson JF. Gut Microbiota and Microbial Metabolism in Early Risk of Cardiometabolic Disease. *Circ Res*. 2023;**132**(12):1674-91. [PubMed ID: 37289901]. [PubMed Central ID: PMC10254080]. <https://doi.org/10.1161/CIRCRESAHA.123.322055>.
13. Ishaq SL, Moses PL, Wright AG. The Pathology of Methanogenic Archaea in Human Gastrointestinal Tract Disease. *The Gut Microbiome - Implications for Human Disease*. 2016. <https://doi.org/10.5772/64637>.
14. Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. *Cancer*. 2003;**98**(5):940-8. [PubMed ID: 12942560]. <https://doi.org/10.1002/cncr.11568>.
15. Bernard JN, Chinnaiyan V, Almeda J, Catala-Valentin A, Andl CD. Lactobacillus sp. Facilitate the Repair of DNA Damage Caused by Bile-Induced Reactive Oxygen Species in Experimental Models of Gastroesophageal Reflux Disease. *Antioxidants (Basel)*. 2023;**12**(7). [PubMed ID: 37507854]. [PubMed Central ID: PMC10376144]. <https://doi.org/10.3390/antiox12071314>.
16. Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy. *Nat Rev Clin Oncol*. 2023;**20**(7):429-52. [PubMed ID: 37169888]. <https://doi.org/10.1038/s41571-023-00766-x>.
17. Baba Y, Iwatsuki M, Yoshida N, Watanabe M, Baba H. Review of the gut microbiome and esophageal cancer: Pathogenesis and potential clinical implications. *Ann Gastroenterol Surg*. 2017;**1**(2):99-104. [PubMed ID: 29863142]. [PubMed Central ID: PMC5881342]. <https://doi.org/10.1002/ags3.12014>.
18. Ramírez-Pérez O, Cruz-Ramón V, Chinchilla-López P, Méndez-Sánchez N. The Role of the Gut Microbiota in Bile Acid Metabolism. *Annals of Hepatology*. 2017;**16**:S21-6. <https://doi.org/10.5604/01.3001.0010.5672>.
19. Chu H, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. *Liver Res*. 2018;**2**(1):43-51. [PubMed ID: 30416839]. [PubMed Central ID: PMC6223644]. <https://doi.org/10.1016/j.livres.2017.11.005>.
20. Sochocka M, Donskow-Lysoniewska K, Diniz BS, Kurpas D, Brzozowska E, Leszek J. The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of Alzheimer's Disease-a Critical Review. *Mol Neurobiol*. 2019;**56**(3):1841-51. [PubMed ID: 29936690]. [PubMed Central ID: PMC6394610]. <https://doi.org/10.1007/s12035-018-1188-4>.
21. Keshavarzi H, Darabi S, Zia Z, Sabbaghziarani F. Effect of Rilmenidine on Substantia Nigra Neurons Injury in a Rat Model of Parkinson's Disease. *Journal of Inflammatory Diseases*. 2023;**27**(3).
22. Li Z, Liang H, Hu Y, Lu L, Zheng C, Fan Y, et al. Gut bacterial profiles in Parkinson's disease: A systematic review. *CNS Neurosci Ther*. 2023;**29**(1):140-57. [PubMed ID: 36284437]. [PubMed Central ID: PMC9804059]. <https://doi.org/10.1111/cns.13990>.
23. Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. *Gastroenterology*. 2013;**145**(5):946-53. [PubMed ID: 24018052]. <https://doi.org/10.1053/j.gastro.2013.08.058>.
24. Choi HH, Cho YS. Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives. *Clin Endosc*. 2016;**49**(3):257-65. [PubMed ID: 26956193]. [PubMed Central ID: PMC4895930]. <https://doi.org/10.5946/ce.2015.117>.
25. Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, et al. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. *Gastroenterology*. 2021;**160**(1):183-192 e3. [PubMed ID: 33011173]. [PubMed Central ID: PMC8034505]. <https://doi.org/10.1053/j.gastro.2020.09.038>.
26. Tariq R, Pardi DS, Bartlett MG, Khanna S. Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. *Clin Infect Dis*. 2019;**68**(8):1351-8. [PubMed ID: 30957161]. <https://doi.org/10.1093/cid/ciy721>.
27. Fehily SR, Basnayake C, Wright EK, Kamm MA. Fecal microbiota transplantation therapy in Crohn's disease: Systematic review. *J Gastroenterol Hepatol*. 2021;**36**(10):2672-86. [PubMed ID: 34169565]. <https://doi.org/10.1111/jgh.15598>.
28. Xiang L, Ding X, Li Q, Wu X, Dai M, Long C, et al. Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment? *Microb Biotechnol*. 2020;**13**(3):760-9. [PubMed ID: 31958884]. [PubMed Central ID: PMC7111085]. <https://doi.org/10.1111/1751-7915.13536>.

29. Qiu B, Liang J, Li C. Effects of fecal microbiota transplantation in metabolic syndrome: A meta-analysis of randomized controlled trials. *PLoS One*. 2023;**18**(7). e0288718. [PubMed ID: 37471410]. [PubMed Central ID: PMC10358997]. <https://doi.org/10.1371/journal.pone.0288718>.
30. Kootte RS, Levin E, Salojärvi J, Smits LP, Hartstra AV, Udayappan SD, et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. *Cell Metab*. 2017;**26**(4):611-619 e6. [PubMed ID: 28978426]. <https://doi.org/10.1016/j.cmet.2017.09.008>.
31. Sood A, Singh A, Midha V, Mahajan R, Kao D, Rubin DT, et al. Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy. *Crohn's Colitis* 360. 2020;**2**(4):otaa067. [PubMed ID: 36777748]. [PubMed Central ID: PMC9802301]. <https://doi.org/10.1093/crocol/otaa067>.
32. Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. *Lancet*. 2017;**389**(10075):1218-28. [PubMed ID: 28214091]. [https://doi.org/10.1016/S0140-6736\(17\)30182-4](https://doi.org/10.1016/S0140-6736(17)30182-4).
33. Kilcoyne A, Kaplan JL, Gee MS. Inflammatory bowel disease imaging: Current practice and future directions. *World J Gastroenterol*. 2016;**22**(3):917-32. [PubMed ID: 26811637]. [PubMed Central ID: PMC4716045]. <https://doi.org/10.3748/wjg.v22.i3.917>.
34. Lam KN, Spanogiannopoulos P, Soto-Perez P, Alexander M, Nalley MJ, Bisanz JE, et al. Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. *Cell Rep*. 2021;**37**(5):109930. [PubMed ID: 34731631]. [PubMed Central ID: PMC8591988]. <https://doi.org/10.1016/j.celrep.2021.109930>.
35. Divya Ganeshan S, Hosseini Z. Phage Therapy with a Focus on the Human Microbiota. *Antibiotics (Basel)*. 2019;**8**(3). [PubMed ID: 31461990]. [PubMed Central ID: PMC6783874]. <https://doi.org/10.3390/antibiotics8030131>.
36. Wortelboer K, de Jonge PA, Scheithauer TPM, Attaye I, Kemper EM, Nieuwdorp M, et al. Phage-microbe dynamics after sterile faecal filtrate transplantation in individuals with metabolic syndrome: a double-blind, randomised, placebo-controlled clinical trial assessing efficacy and safety. *Nat Commun*. 2023;**14**(1):5600. [PubMed ID: 37699894]. [PubMed Central ID: PMC10497675]. <https://doi.org/10.1038/s41467-023-41329-z>.
37. Han Q, Li J, Li Z, Aishajiang R, Yu D. Novel therapeutic strategies and recent advances in gut microbiota synergy with nanotechnology for colorectal cancer treatment. *Mater Today Bio*. 2025;**31**:101601. [PubMed ID: 40066079]. [PubMed Central ID: PMC11891152]. <https://doi.org/10.1016/j.mtbio.2025.101601>.
38. Le TS, Southgate PC, O'Connor W, Abramov T, Shelley D, V. Vu S, et al. Use of Bacteriophages to Control Vibrio Contamination of Microalgae Used as a Food Source for Oyster Larvae During Hatchery Culture. *Curr Microbiol*. 2020;**77**(8):1811-20. [PubMed ID: 32328752]. <https://doi.org/10.1007/s00284-020-01981-w>.
39. Cho YS, Han K, Xu J, Moon JJ. Novel strategies for modulating the gut microbiome for cancer therapy. *Adv Drug Deliv Rev*. 2024;**210**:115332. [PubMed ID: 38759702]. [PubMed Central ID: PMC11268941]. <https://doi.org/10.1016/j.addr.2024.115332>.
40. Arnold J, Glazier J, Mimm M. Genetic Engineering of Resident Bacteria in the Gut Microbiome. *J Bacteriol*. 2023;**205**(7). e0012723. [PubMed ID: 37382533]. [PubMed Central ID: PMC10367592]. <https://doi.org/10.1128/jb.00127-23>.
41. Perler BK, Friedman ES, Wu GD. The Role of the Gut Microbiota in the Relationship Between Diet and Human Health. *Annu Rev Physiol*. 2023;**85**:449-68. [PubMed ID: 36375468]. <https://doi.org/10.1146/annurev-physiol-031522-092054>.
42. Koutoukidis DA, Jebb SA, Zimmerman M, Otunla A, Henry JA, Ferrey A, et al. The association of weight loss with changes in the gut microbiota diversity, composition, and intestinal permeability: a systematic review and meta-analysis. *Gut Microbes*. 2022;**14**(1):2020068. [PubMed ID: 35040746]. [PubMed Central ID: PMC8796717]. <https://doi.org/10.1080/19490976.2021.2020068>.
43. Merra G, Noce A, Marrone G, Cintoni M, Tarsitano MG, Capacci A, et al. Influence of Mediterranean Diet on Human Gut Microbiota. *Nutrients*. 2020;**13**(1). [PubMed ID: 33375042]. [PubMed Central ID: PMC7822000]. <https://doi.org/10.3390/nu13010007>.
44. Khavandegar A, Heidarzadeh A, Angoorani P, Hasani-Ranjbar S, Ejtahed HS, Larijani B, et al. Adherence to the Mediterranean diet can beneficially affect the gut microbiota composition: a systematic review. *BMC Med Genomics*. 2024;**17**(1):91. [PubMed ID: 38632620]. [PubMed Central ID: PMC11022496]. <https://doi.org/10.1186/s12920-024-01861-3>.
45. Ang QY, Alexander M, Newman JC, Tian Y, Cai J, Upadhyay V, et al. Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells. *Cell*. 2020;**181**(6):1263-1275 e16. [PubMed ID: 32437658]. [PubMed Central ID: PMC7293577]. <https://doi.org/10.1016/j.cell.2020.04.027>.
46. Grembi JA, Nguyen LH, Haggerty TD, Gardner CD, Holmes SP, Parsonnet J. Gut microbiota plasticity is correlated with sustained weight loss on a low-carb or low-fat dietary intervention. *Sci Rep*. 2020;**10**(1):1405. [PubMed ID: 31996717]. [PubMed Central ID: PMC6989501]. <https://doi.org/10.1038/s41598-020-58000-y>.
47. Li L, Zhao X, Abdugheni R, Yu F, Zhao Y, Ma BF, et al. Gut microbiota changes associated with low-carbohydrate diet intervention for obesity. *Open Life Sci*. 2024;**19**(1):20220803. [PubMed ID: 38299011]. [PubMed Central ID: PMC10828666]. <https://doi.org/10.1515/biol-2022-0803>.
48. Duan X, Zhang L, Liao Y, Lin Z, Guo C, Luo S, et al. Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet. *Eur J Pharmacol*. 2024;**969**:176440. [PubMed ID: 38402930]. <https://doi.org/10.1016/j.ejphar.2024.176440>.
49. Chandrasekaran P, Weiskirchen S, Weiskirchen R. Effects of Probiotics on Gut Microbiota: An Overview. *Int J Mol Sci*. 2024;**25**(11). [PubMed ID: 38892208]. [PubMed Central ID: PMC1172883]. <https://doi.org/10.3390/ijms25116022>.
50. Song M, Jin J, Lim JE, Kou J, Pattanayak A, Rehman JA, et al. TLR4 mutation reduces microglial activation, increases Abeta deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. *J Neuroinflammation*. 2011;**8**:92. [PubMed ID: 21827663]. [PubMed Central ID: PMC3169468]. <https://doi.org/10.1186/1742-2094-8-92>.